|法舒地尔|CsnPharm

CAS No.: 103745-39-7

Fasudil/法舒地尔 Catalog No. CSN10983

Synonyms: HA-1077;AT877;法舒地尔

Fasudil HCl is a potent inhibitor of ROCK-II, PKA, PKG, PKC, and MLCK with Ki of 0.33 μM, 1.6 μM, 1.6 μM, 3.3 μM and 36 μM, respectively.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Fasudil hydrochloride is a potent inhibitor of ROCK-II, PKA, PKG, PKC, and MLCK with Ki of 0.33 μM, 1.6 μM, 1.6 μM, 3.3 μM and 36 μM, respectively.
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01069042	Heart Failure	Phase 4	Unknown	November 2010	Taiwan ... more >> National Cheng Kung University Hospital Recruiting Tainan, Taiwan, 70401 Contact: Ping-Yen Liu, MD, PhD Collapse <<
NCT03404843	Cardiovascular Diseases	Phase 2	Completed	-	United States, Colorado ... more >> Colorado State University, Dept. of Health and Exercise Science Fort Collins, Colorado, United States, 80523 Collapse <<
NCT01823081	Diabetic Macular Edema	Phase 3	Completed	-	Iran, Islamic Republic of ... more >> Tehran, Iran, Islamic Republic of Collapse <<

更多
参考文献

[1] Zhang J, Li XX, et al. Inhibition of the activity of Rho-kinase reduces cardiomyocyte apoptosis in heart ischemia/reperfusion via suppressing JNK-mediated AIF translocation. Clin Chim Acta. 2009 Mar;401(1-2):76-80.
[2] Ono-Saito N, Niki I, et al. H-series protein kinase inhibitors and potential clinical applications. Pharmacol Ther. 1999 May-Jun;82(2-3):123-31.

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 3.4321 mL
- 17.1604 mL
- 34.3208 mL
- 5 mM
- 0.6864 mL
- 3.4321 mL
- 6.8642 mL
- 10 mM
- 0.3432 mL
- 1.7160 mL
- 3.4321 mL

技术信息

CAS号	103745-39-7	储存条件	粉末 Keep in dark place,Sealed in dry,Store in freezer, under -20°C 液体 -20°C:3-6 月 -80°C:12月
分子式	C14H17N3O2S	运输	蓝冰
分子量	291.37	别名	HA-1077;AT877;法舒地尔

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01069042	Heart Failure	Phase 4	Unknown	November 2010	Taiwan ... more >> National Cheng Kung University Hospital Recruiting Tainan, Taiwan, 70401 Contact: Ping-Yen Liu, MD, PhD Collapse <<
NCT03404843	Cardiovascular Diseases	Phase 2	Completed	-	United States, Colorado ... more >> Colorado State University, Dept. of Health and Exercise Science Fort Collins, Colorado, United States, 80523 Collapse <<
NCT01823081	Diabetic Macular Edema	Phase 3	Completed	-	Iran, Islamic Republic of ... more >> Tehran, Iran, Islamic Republic of Collapse <<
NCT00670202	Carotid Stenosis	Phase 2	Terminated(Slow enrollment)	-	United States, Massachusetts ... more >> Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Collapse <<
NCT00498615	Raynaud Scler... more >>oderma Collapse <<	Phase 3	Completed	-	United States, Maryland ... more >> Johns Hopkins University Baltimore, Maryland, United States, 21224 Collapse <<
NCT03391219	Retinal Vein Occlusion	Phase 2 Phase 3	Recruiting	October 2018	Iran, Islamic Republic of ... more >> Ophthalmic Research Center Recruiting Tehran, Iran, Islamic Republic of Contact: Ramin Noorinia, MD 009822591616 labbafi@hotmail.com Collapse <<
NCT00670202	-	-	Terminated(Slow enrollment)	-	-
NCT01935518	Amyotrophic Lateral Sclerosis	Phase 2	Unknown	May 2015	China ... more >> Peking University Third Hospital Recruiting Beijing, China, 100191 Contact: Xiaolu Liu, MD 0086-1082265032 liuxiaolupku@gmail.com Principal Investigator: Dongsheng Fan, MD, PhD Collapse <<
NCT00498615	-	-	Completed	-	-
NCT00120718	Atherosclerosis ... more >> Hypercholesterolemia Collapse <<	Phase 2	Completed	-	United States, Massachusetts ... more >> Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Collapse <<
NCT03753269	ST Segment Elevation Myocardia... more >>l Infarction Collapse <<	Phase 4	Not yet recruiting	December 30, 2022	-

Fasudil/法舒地尔 Catalog No. CSN10983

靶点选择性

请登录您的专属账户

确认信息